CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profile in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Porter’s five forces analysis
3.3.Top player positioning, 2020
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.Increase in infertility rate
3.4.1.2.Delayed pregnancies
3.4.1.3.Technological advancements in ultrasound-guided infertility diagnosis
3.4.1.4.Increase in disposable income and rise in awareness regarding infertility treatment

3.4.2.Restraint

3.4.2.1.High cost for infertility diagnosis and treatment

3.4.3.Opportunity

3.4.3.1.Rise in trend of fertility tourism

3.4.4.Impact analysis

3.5.Impact analysis of COVID-19 on the market
3.6.Company profiles of ultrasound providers in infertility diagnosis and treatment market

3.6.1.CANON INC. (CANON MEDICAL SYSTEMS CORPORATION)

3.6.1.1.Company overview
3.6.1.2.Company snapshot
3.6.1.3.Operating business segments
3.6.1.4.Product portfolio
3.6.1.5.Business performance

3.6.2.GENERAL ELECTRIC COMPANY (GE HEALTHCARE)

3.6.2.1.Company overview
3.6.2.2.Company snapshot
3.6.2.3.Operating business segments
3.6.2.4.Product portfolio
3.6.2.5.Business performance
3.6.2.6.Key strategic moves and developments

3.6.3.KONINKLIJKE PHILIPS N.V

3.6.3.1.Company overview
3.6.3.2.Company snapshot
3.6.3.3.Operating business segments
3.6.3.4.Product portfolio
3.6.3.5.Business performance
3.6.3.6.Key strategic moves and developments

3.6.4.MINDRAY MEDICAL INTERNATIONAL LIMITED

3.6.4.1.Company overview
3.6.4.2.Company snapshot
3.6.4.3.Operating business segments
3.6.4.4.Product portfolio

3.6.5.SIEMENS AG

3.6.5.1.Company overview
3.6.5.2.Company snapshot
3.6.5.3.Operating business segments
3.6.5.4.Product portfolio
3.6.5.5.Business performance
3.6.5.6.Key strategic moves and developments

CHAPTER 4:FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY

4.1.Overview

4.1.1.Market size and forecast

4.2.Infertility diagnostics

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by type

4.2.2.1.Hysterosonography

4.2.2.1.1.Market size and forecast

4.2.2.2.Hysterosonosalpyngography

4.2.2.2.1.Market size and forecast

4.2.2.3.Hysterosalpingo-foam sonography (HyFoSy)

4.2.2.3.1.Market size and forecast

4.3.Punction

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type

4.3.2.1.Ultrasound-guided trans-vaginal needle aspiration/biopsy

4.3.2.1.1.Market size and forecast

4.3.2.2.Ultrasound-guided core-needle testicular biopsy

4.3.2.2.1.Market size and forecast

4.4.Treatment monitoring

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type

4.4.2.1.Frozen embryo transfer

4.4.2.1.1.Market size and forecast

4.4.2.2.Ovulation monitoring

4.4.2.2.1.Market size and forecast

CHAPTER 5:FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER

5.1.Overview

5.1.1.Market size and forecast

5.2.Public hospital with infertility department

5.2.1.Key market trends, growth factors, and opportunities
5.2.2.Market size and forecast, by care pathway

5.2.2.1.Infertility diagnostics

5.2.2.1.1.Market size and forecast

5.2.2.2.Punction

5.2.2.2.1.Market size and forecast

5.2.2.3.Treatment monitoring

5.2.2.3.1.Market size and forecast

5.3.Private fertility clinics

5.3.1.Key market trends, growth factors, and opportunities
5.3.2.Market size and forecast, by care pathway

5.3.2.1.Infertility diagnostics

5.3.2.1.1.Market size and forecast

5.3.2.2.Punction

5.3.2.2.1.Market size and forecast

5.3.2.3.Treatment monitoring

5.3.2.3.1.Market size and forecast

5.4.Ambulatory centers

5.4.1.Key market trends, growth factors, and opportunities
5.4.2.Market size and forecast, by care pathway

5.4.2.1.Infertility diagnostics

5.4.2.1.1.Market size and forecast

5.4.2.2.Punction

5.4.2.2.1.Market size and forecast

5.4.2.3.Treatment monitoring

5.4.2.3.1.Market size and forecast

CHAPTER 6:COMPANY PROFILES

6.1.AMERICAN HOSPITAL 0F PARIS

6.1.1.Company overview
6.1.2.Company snapshot
6.1.3.Operating business segments
6.1.4.Product portfolio

6.2.AMP CENTER ST ROCH

6.2.1.Company overview
6.2.2.Company snapshot
6.2.3.Operating business segments
6.2.4.Product portfolio

6.3.AMP NATECIA LYON

6.3.1.Company overview
6.3.2.Company snapshot
6.3.3.Operating business segments
6.3.4.Product portfolio

6.4.CENTRE CHIRUGICAL (PIERRE CHEREST CLINIC)

6.4.1.Company overview
6.4.2.Company snapshot
6.4.3.Operating business segments
6.4.4.Product portfolio

6.5.FERTILITY CENTER-PARSI EAST

6.5.1.Company overview
6.5.2.Company snapshot
6.5.3.Operating business segments
6.5.4.Product portfolio

6.6.HOSPITAL COCHIN

6.6.1.Company overview
6.6.2.Company snapshot
6.6.3.Operating business segments
6.6.4.Product portfolio

6.7.HOSPITAL GROUP DIACONESSES CROIX SAINT-SIMON

6.7.1.Company overview
6.7.2.Company snapshot
6.7.3.Operating business segments
6.7.4.Product portfolio

6.8.MATERNITÉ DES BLUETS - HOSPITAL PIERRE ROUQUÈS

6.8.1.Company overview
6.8.2.Company snapshot
6.8.3.Operating business segment
6.8.4.Product portfolio

6.9.POINTGYN - PLEASURE

6.9.1.Company overview
6.9.2.Company snapshot
6.9.3.Operating business segments
6.9.4.Product portfolio

6.10.RAMSAY HEALTHCARE LIMITED (CLINIQUE DE LA MUETTE)

6.10.1.Company overview
6.10.2.Company snapshot
6.10.3.Operating business segments
6.10.4.Product portfolio
6.10.5.Business performance

LIST OF TABLES

TABLE 01.CANON: COMPANY SNAPSHOT
TABLE 02.CANON: OPERATING SEGMENTS
TABLE 03.CANON: PRODUCT PORTFOLIO
TABLE 04.GE: COMPANY SNAPSHOT
TABLE 05.GE: PRODUCT SEGMENTS
TABLE 06.GE: PRODUCT PORTFOLIO
TABLE 07.GE: KEY DEVELOPMENTS
TABLE 08.PHILIPS: COMPANY SNAPSHOT
TABLE 09.PHILIPS: PRODUCT SEGMENTS
TABLE 10.PHILIPS: PRODUCT PORTFOLIO
TABLE 11.PHILIPS: KEY DEVELOPMENTS
TABLE 12.MINDRAY: COMPANY SNAPSHOT
TABLE 13.MINDRAY: OPERATING SEGMENTS
TABLE 14.MINDRAY: PRODUCT PORTFOLIO
TABLE 15.SIEMENS: COMPANY SNAPSHOT
TABLE 16.SIEMENS: OPERATING BUSINESS SEGMENTS
TABLE 17.SIEMENS: PRODUCT PORTFOLIO
TABLE 18.SIEMENS: KEY DEVELOPMENTS
TABLE 19.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY CARE PATHWAY, 2020–2030 ($MILLION)
TABLE 20.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, BY TYPE, 2020–2030 ($MILLION)
TABLE 21.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, BY TYPE, 2020–2030($MILLION)
TABLE 22.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, BY TYPE, 2020–2030 ($MILLION)
TABLE 23.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET, BY END USER, 2020–2030 ($MILLION)
TABLE 24.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUBLIC HOSPITAL WITH INFERTILITY DEPARTMENT, BY CARE PATHWAY, 2020–2030 ($MILLION)
TABLE 25.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PRIVATE FERTILITY CLINICS, BY CARE PATHWAY 2020–2030 ($MILLION)
TABLE 26.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR AMBULATORY CENTERS, BY CARE PATHWAY 2020–2030 ($MILLION)
TABLE 27.AMERICAN HOSPITAL: COMPANY SNAPSHOT
TABLE 28.AMERICAN HOSPITAL: OPERATING SEGMENT
TABLE 29.AMERICAN HOSPITAL: PRODUCT PORTFOLIO
TABLE 30.ST ROCH: COMPANY SNAPSHOT
TABLE 31.ST ROCH: OPERATING SEGMENTS
TABLE 32.ST ROCH: PRODUCT PORTFOLIO
TABLE 33.NATECIA: COMPANY SNAPSHOT
TABLE 34.NATECIA: OPERATING SEGMENTS
TABLE 35.NATECIA: PRODUCT PORTFOLIO
TABLE 36.CHIRUGICAL: COMPANY SNAPSHOT
TABLE 37.CHIRUGICAL: OPERATING SEGMENT
TABLE 38.CENTRE CHIRUGICAL: PRODUCT PORTFOLIO
TABLE 39.FERTILITY CENTER: COMPANY SNAPSHOT
TABLE 40.FERTILITY CENTER: OPERATING SEGMENT
TABLE 41.FERTILITY CENTER: PRODUCT PORTFOLIO
TABLE 42.COCHIN: COMPANY SNAPSHOT
TABLE 43.COCHIN: OPERATING SEGMENTS
TABLE 44.COCHIN: PRODUCT PORTFOLIO
TABLE 45.DIACONESSES: COMPANY SNAPSHOT
TABLE 46.DIACONESSES: OPERATING SEGMENT
TABLE 47.DIACONESSES: PRODUCT PORTFOLIO
TABLE 48.BLUETS: COMPANY SNAPSHOT
TABLE 49.BLUETS: OPERATING SEGMENTS
TABLE 50.BLUETS: PRODUCT PORTFOLIO
TABLE 51.POINTGYN: COMPANY SNAPSHOT
TABLE 52.POINTGYN: OPERATING SEGMENT
TABLE 53.POINTGYN: PRODUCT PORTFOLIO
TABLE 54.RAMSAY: COMPANY SNAPSHOT
TABLE 55.RAMSAY: OPERATING SEGMENTS
TABLE 56.RAMSAY: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET SEGMENTATION
FIGURE 02.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 03.MODERATE BARGAINING POWER OF BUYERS
FIGURE 04.MODERATE THREAT OF SUBSTITUTES
FIGURE 05.HIGH THREAT OF NEW ENTRANTS
FIGURE 06.MODERATE INTENSITY OF RIVALRY
FIGURE 07.TOP PLAYER POSITIONING, 2020
FIGURE 08.IMPACT ANALYSIS
FIGURE 09.CANON: NET SALES, 2018–2020 ($MILLION)
FIGURE 10.CANON: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 11.CANON: REVENUE SHARE BY REGION, 2020(%)
FIGURE 12.GE: NET SALES, 2018–2020 ($MILLION)
FIGURE 13.GE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 14.GE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 15.PHILIPS: NET SALES, 2018–2020 ($MILLION)
FIGURE 16.PHILIPS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 17.PHILIPS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 18.SIEMENS: NET SALES, 2018–2020 ($MILLION)
FIGURE 19.SIEMENS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.SIEMENS: REVENUE SHARE BY REGION, 2020(%)
FIGURE 21.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYSTEROSONOGRAPHY, 2020–2030 ($MILLION)
FIGURE 22.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYSTEROSONOSALPYNGOGRAPHY , 2020–2030 ($MILLION)
FIGURE 23.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR HYFOSY, 2020–2030 ($MILLION)
FIGURE 24.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR ULTRASOUND GUIDED TRANS-VAGINAL NEEDLE ASPIRATION/BIOPSY, 2020–2030 ($MILLION)
FIGURE 25.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR ULTRASOUND GUIDED CORE-NEEDLE TESTICULAR BIOPSY, 2020–2030 ($MILLION)
FIGURE 26.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR FROZEN EMBRYO TRANSFER, 2020–2030 ($MILLION)
FIGURE 27.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR OVULATION MONITORING, 2020–2030 ($MILLION)
FIGURE 28.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 29.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 30.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 31.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 32.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 33.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 34.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR INFERTILITY DIAGNOSTICS, 2020–2030 ($MILLION)
FIGURE 35.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR PUNCTION, 2020–2030 ($MILLION)
FIGURE 36.FRANCE ULTRASOUND INFERTILITY DIAGNOSIS & TREATMENT MARKET FOR TREATMENT MONITORING, 2020–2030 ($MILLION)
FIGURE 37.RAMSAY: NET SALES, 2019–2021 ($MILLION)
FIGURE 38.RAMSAY: REVENUE SHARE, BY SEGMENT, 2021 (%)

This section provides the opinions of the top level CXOs in the France ultrasound infertility diagnosis and treatment market. According to the insights of CXOs, the market is expected to exhibit high growth due to increase in incidence of infertility issues, rise in trend of delayed pregnancies, and technological advancements for determination of infertility diagnosis & treatment monitoring services.

The CXOs further added that increase in smoking & tobacco usage, rise in alcohol consumption, rise in number of overweight & obese individuals, surge in prevalence of sexually transmitted diseases (STDs) lead to infertility disorders among males and females, thus strengthening the market growth.

Moreover, surge in demand for IVF due to its success rates and recent approval of the law in France of allowing single women and lesbians to get fertility treatment and access to medically assisted reproduction, including artificial insemination and IVF are anticipated to boost fertility tourism across the country.